日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sabotaging TCR signaling-LAG3 interferes with the CD3ε-LCK interaction

破坏TCR信号传导——LAG3干扰CD3ε-LCK相互作用

Fiala, Gina J; Schamel, Wolfgang W

Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab

LAG3单核苷酸多态性对接受Glofitamab治疗的复发难治性弥漫性大B细胞淋巴瘤患者的临床影响

Ullmann, Maeva; Seipel, Katja; Nilius, Henning; Bertschinger, Martina; Rentsch, Vera; Bacher, Ulrike; Pabst, Thomas

Correction: Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma

更正:多组学分析揭示了LAG3作为预后和免疫生物标志物的潜力及其在骨肉瘤中的验证

Cao, Qianqian; Zhang, Yuzhe; Cheng, Cheng; Wang, Xiaoyang; Fan, Panlong; Huang, Jincheng; Dai, Zhipeng

LAG3 constrains anti-parasitic response by effector CD4(+) T-cell in early Echinococcus multilocularis-infected mice.

LAG3 限制了早期感染多房棘球绦虫的小鼠体内效应 CD4(+) T 细胞的抗寄生虫反应。

Ainiwaer Abidan, Li Dewei, Liu Wenge, Deng Bingqing, Li Yinshi, Xiao Wenying, Sun Sheng, Gao Yi, Tang Na, Ge Conghui, Li Jing, Wang Hui, Zhang Chuanshan

Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma

综合分析揭示了LAG3在胶质瘤T细胞耗竭中的关键作用

Wang, Zheng; Fu, Haitao; Li, Yuwei; Liu, Zewei; Fan, Wenhua; Liu, Yuqing; Zhang, Chuanbao; Liang, Jingshan; Zhang, Zhong; Zhong, Liyun; Yan, Wei

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma

长期生存率和生物标志物分析评估新辅助联合辅助治疗瑞拉利单抗(抗LAG3)和纳武利尤单抗(抗PD-1)在可切除黑色素瘤患者中的疗效

Burton, Elizabeth M; Milton, Denái R; Tetzlaff, Michael T; Wani, Khalida; Ross, Merrick I; Postow, Michael A; Lazcano, Rossana; Glitza, Isabella C; Wong, Michael K; Patel, Sapna P; Diab, Adi; Gershenwald, Jeffrey E; McQuade, Jennifer L; Betof Warner, Allison; Prieto, Victor G; Lee, Jeffrey E; Goepfert, Ryan P; Fisher, Sarah B; Song, Addison; Malke, Jared; Simon, Julie M; Ariyan, Charlotte; Torres-Cabala, Carlos A; Davies, Michael A; Lazar, Alexander; Wargo, Jennifer A; Tawbi, Hussein A; Amaria, Rodabe N

Advances in LAG3 cancer immunotherapeutics

LAG3癌症免疫疗法的进展

Adam, Kieran; Butler, Samuel C; Workman, Creg J; Vignali, Dario A A

LAG3 regulates antibody responses in a murine model of kidney transplantation

LAG3在小鼠肾移植模型中调节抗体反应

Nicosia, Michael; Fan, Ran; Lee, Juyeun; All, Gabriella; Gorbacheva, Victoria; Valenzuela, José I; Yamamoto, Yosuke; Beavers, Ashley; Dvorina, Nina; Baldwin, William M 3rd; Chuluyan, Eduardo; Araki, Motoo; Gaudette, Brian T; Fairchild, Robert L; Min, Booki; Valujskikh, Anna

Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma

Ce6衍生物光动力疗法通过阻断LAG3诱导PANoptosis并增强皮肤鳞状细胞癌的抗肿瘤免疫力

Diyan Chen ,Bo Wang ,Chunying Li ,Hui Tao ,Fangqi Lu ,Zhijie Ruan ,Zijun Zhao ,Chunxiao Li ,Guorong Yan ,Haiyan Zhang ,Yeqiang Liu ,Xiuli Wang ,Guolong Zhang ,Qingyu Zeng

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients

使用液体活检生物标志物制定风险评分,以选择免疫疗法反应者并对转移性黑色素瘤患者的疾病进展风险进行分层

Amalia Azzariti, Simona De Summa, Tommaso M Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida